| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 4 securities · may seek to influence control | ||||||
|
Atara Biotherapeutics, Inc.
13D/A
ATRA · 046513107
|
16.1% |
5/11/2026
Event 5/7/2026
|
||||
| Panacea Innovation Limited | 16.1% | |||||
| Panacea Venture Healthcare Fund II, L.P. | 12.4% | |||||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 12.4% | |||||
| Panacea Opportunity Fund I, L.P. | 3.8% | |||||
| Panacea Opportunity Fund I GP Company, Ltd. | 3.8% | |||||
| James Huang | 16.1% | |||||
|
Connect Biopharma Holdings Limited
13D/A
CNTB · G23549101
|
21.2% |
4/1/2026
Event 3/31/2026
|
||||
| Panacea Innovation Limited | 21.2% | |||||
| Panacea Venture Healthcare Fund II, L.P. | 21.2% | |||||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 21.2% | |||||
| James Huang | 21.2% | |||||
|
CASI Pharmaceuticals, Inc.
13D/A
CASIF · G1933S101
|
22.5% |
12/17/2025
Event 12/16/2025
|
||||
| Panacea Venture Healthcare Fund II, L.P. | 22.0% | |||||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 22.0% | |||||
| Panacea Innovation Limited | 22.0% | |||||
| James Huang | 22.5% | |||||
|
Connect Biopharma Holdings Limited
13D/A
CNTB · 207523101
|
25.1% |
7/21/2025
Event 7/21/2025
|
||||
| Panacea Innovation Limited | 25.1% | |||||
| Panacea Venture Healthcare Fund II, L.P. | 25.1% | |||||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 25.1% | |||||
| James Huang | 25.1% | |||||
| Schedule 13G · 4 securities · passive | ||||||
|
Adagene Inc.
13G/A
ADAG · 005329107
|
3.8% |
11/14/2025
Event 9/30/2025
|
||||
| Panacea Venture Healthcare Fund II, L.P. | 3.8% | |||||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 3.8% | |||||
| Panacea Innovation Limited | 3.8% | |||||
| James Huang | 3.8% | |||||
|
Marinus Pharmaceuticals, Inc.
13G/A
MRNS · 56854Q200
|
0% |
2/14/2025
Event 12/31/2024
|
||||
| Panacea Venture Healthcare Fund II, L.P. | 0% | |||||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 0% | |||||
| Panacea Innovation Limited | 0% | |||||
| James Huang | 0% | |||||
|
Amylyx Pharmaceuticals, Inc.
13G/A
AMLX · 03237H101
|
2.6% |
2/14/2025
Event 12/31/2024
|
||||
| Panacea Venture Healthcare Fund II, L.P. | 2.6% | |||||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 2.6% | |||||
| Panacea Innovation Limited | 2.6% | |||||
| James Huang | 2.6% | |||||
|
Atara Biotherapeutics, Inc.
13G
ATRA · 046513206
|
9.5% |
2/6/2025
Event 1/30/2025
|
||||
| Panacea Venture Healthcare Fund II, L.P. | 9.5% | |||||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 9.5% | |||||
| Panacea Innovation Limited | 9.5% | |||||
| James Huang | 9.5% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.